TrialAsian Pacific journal of cancer prevention : APJCP2024
Comparing Ribociclib versus Palbociclib as a Second Line Treatment in Combination with Fulvestrant in Metastatic Breast Cancer: A Randomized Clinical Trial.
Manar Hamed Ahmed Shaaban et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.